Prostatype Genomics AB Financial Flexibility Index
Prostatype Genomics AB financial flexibility index. Prostatype Genomics AB (PROGEN) has a Financial Flexibility Index of -1.15x as of June 2025. Free cash flow of Skr-8.43 Million (operating CF Skr-8.54 Million minus capex Skr114.50K) represents -1% of total liabilities (Skr7.36 Million). See Prostatype Genomics AB (PROGEN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Prostatype Genomics AB (2016–2024)
Financial flexibility index of Prostatype Genomics AB from 2016 to 2024. Historical Financial Flexibility Index trend for Prostatype Genomics AB across 8 annual periods. Explore PROGEN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Prostatype Genomics AB Financial Flexibility Index by Year (2016–2024)
Prostatype Genomics AB financial flexibility index by year from 2016 to 2024. Year-by-year free cash flow to debt coverage for Prostatype Genomics AB. For the full cash flow conversion analysis, see PROGEN operating cash flow.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.33x | Skr-36.85 Million | Skr-44.71 Million | Skr8.50 Million | ▼ -417.1% |
| 2023 | -0.84x | Skr-20.58 Million | Skr-29.14 Million | Skr24.55 Million | ▲ +85.5% |
| 2022 | -5.77x | Skr-27.69 Million | Skr-27.69 Million | Skr4.80 Million | ▼ -82.6% |
| 2021 | -3.16x | Skr-13.58 Million | Skr-16.08 Million | Skr4.30 Million | ▼ -15.6% |
| 2020 | -2.73x | Skr-14.69 Million | Skr-14.71 Million | Skr5.37 Million | ▼ -287.4% |
| 2018 | -0.71x | Skr-6.37 Million | Skr-9.63 Million | Skr9.03 Million | ▼ -807.7% |
| 2017 | -0.08x | Skr-1.05 Million | Skr-5.71 Million | Skr13.49 Million | ▲ +96.1% |
| 2016 | -2.01x | Skr-9.60 Million | Skr-9.63 Million | Skr4.79 Million | — |